Monitoring Progression in Hypertensive Patients with Dyslipidemia Using Optical Coherence Tomography Angiography: Can A.I. Be Improved?

利用光学相干断层扫描血管造影术监测高血压合并血脂异常患者的病情进展:人工智能能否得到改进?

阅读:1

Abstract

Background: With the development of artificial intelligence (A.I.), the optical coherence tomography angiography (OCTA) analysis of progression in hypertensive retinopathy could be improved. Our purpose was to use the OCTA to study the effect of uncontrolled dyslipidemia and hypertensive retinopathy on the retinal microvasculature and to identify a potential software update of the A.I. secondary to the OCTA analysis. By using our most relevant data, the A.I. software can be upgraded by introducing new mathematic formulas between the OCTA parameters and the lipid level. Methods: We performed a prospective cohort study on 154 eyes of participants from Eastern Europe. We used a standardized protocol to collect data on past medical history of dyslipidemia and hypertension and OCTA to measure retinal vascular parameters. Results: The average age of the participants was 56.9 ± 9.1, with a minimum of 34 and a maximum of 82 and with a higher percentage of males: 55.8%. Statistically significant correlations were found for total cholesterol and skeleton total (r = -0.249; p = 0.029), foveal avascular zone (FAZ), circularity and low-density lipoprotein (LDL) (r = 0.313; p = 0.006), non-flow area (NFA) and LDL (r = 0.233; p = 0.042), and vascular flow area (VFA) and LDL (r = -0.354; p = 0.002). Conclusions: Subjects with dyslipidemia and progressive hypertensive retinopathy had a reduction in microvascular density and vascular flow, a focal capillary non-perfusion, and an increased FAZ. Thus, by improving the A.I. system, our research aims to provide better OCTA monitoring, which could help in the early-stage detection of progression and development of A.I. screening programs, leading to increased efficiency in diagnosing patients.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。